• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·HKPD
Share

Cellyan Biotechnology Co., Ltd Stocks

$ 0.39Last Updated 24.06.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 3.95M

$ 0.39
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA, und

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.06.2026 03:02

Bain has revised its forecast for luxury market growth downward. Why is it talking about a recovery in the industry?

26.06.2026 01:29

Market Split: Nasdaq Falls for the Fourth Consecutive Day Despite a Rally in Chipmakers

26.06.2026 00:48

Qualcomm will produce AI chips for Meta's data centers. Its stock soared

26.06.2026 00:13

Citigroup raised its price target for SanDisk by 23%. Its stock has already risen 860% in 2026

25.06.2026 23:22

Iran Attacked a Cargo Ship in the Strait of Hormuz — WSJ. Oil Prices Rise

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026